BELLUS Health Inc primarily operates in the biopharmaceutical industry.

The main competitors of BELLUS Health Inc in the market include pharmaceutical companies such as Pfizer, Johnson & Johnson, and Novartis. These companies are also involved in the research, development, and production of various drugs and treatments. By consistently monitoring the market activities of these competitors, BELLUS Health Inc can stay competitive and continually innovate in order to meet the needs and demands of its customers.

BELLUS Health Inc is a Canadian biopharmaceutical company focused on the development of innovative therapies for conditions affecting the kidney and central nervous system. Founded in 1993, BELLUS Health has a strong history of research and collaboration, aiming to address unmet medical needs. The company has a diverse pipeline of drug candidates, including its lead product candidate, BLU-5937, which aims to treat chronic cough. BELLUS Health is committed to advancing therapies that improve patients' quality of life and has garnered recognition for its dedication to scientific excellence and innovation in the field of biopharmaceuticals.

BELLUS Health Inc has achieved significant milestones in its journey. The company successfully completed its Phase 2a clinical study for BLU-5937, a treatment for chronic cough. Additionally, BELLUS Health Inc received Fast Track designation from the U.S. FDA for BLU-5937, indicating its potential to address a significant unmet medical need. Furthermore, the company entered into a collaboration agreement with NEOMED-LABS to support the development of BLU-5937. This collaboration enhances BELLUS Health Inc's clinical development capabilities and expertise. These achievements reflect the company's commitment to advancing innovative solutions for patients globally, underscoring its position in the healthcare industry.

BELLUS Health Inc is primarily present in North America, with a focus on Canada and the United States.

BELLUS Health Inc represents values of innovation, integrity, and excellence in the biopharmaceutical industry. The company's corporate philosophy is centered around improving the health and well-being of individuals by developing and commercializing novel therapies. BELLUS Health Inc believes in conducting business with transparency, adhering to ethical practices, and nurturing a collaborative environment for growth and success. With a focus on research and development, the company strives to provide innovative solutions to address unmet medical needs. BELLUS Health Inc's commitment to advancing healthcare through scientific advancement sets them apart in the industry.

10 analysts currently rate the BELLUS Health stock: 6 recommend buying, 4 holding and 0 selling.

BELLUS Health Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the BELLUS Health share trades at 1,61 EUR (1,86 USD).

The BELLUS Health share (BLU.TO) is listed on 5 stock exchanges, including: NASDAQ (BLU), Frankfurt (BHN0.F), München (BHN0.MU), Düsseldorf (BHN0.DU), London (0A4U.L).

BELLUS Health Inc is a biopharmaceutical company that operates in the fields of dermatology, plant medicine, and neurology. The company's goal is to develop new treatment methods for diseases and contribute to improving the quality of life for patients. The company focuses on high standards in researching and developing medications and therapies. BELLUS Health Inc offers a wide range of products in dermatology, including topical creams and solutions for treating skin conditions. One example is the medication Solabegron, used to treat rosacea. Another important product line in dermatology is BELLUS Health Inc's medical devices for laser therapy of acne. In plant medicine, BELLUS Health Inc researches natural remedies, mainly active substances derived from plant extracts. A significant medication in this field is Kinetin, used for cosmetic treatment of skin aging. BELLUS Health Inc also focuses on treating central nervous system diseases. The company conducts intensive research in developing new approaches for treating neurodegenerative diseases such as Alzheimer's and Parkinson's. BELLUS Health Inc employs innovative therapy concepts, such as antibody-based treatments. Alongside research and development, distributing medications and medical devices forms an important business area for BELLUS Health Inc. The company collaborates closely with pharmacies and hospitals to provide patients with access to the latest treatment methods. BELLUS Health Inc also has a network of strategic partners in the pharmaceutical industry and scientific field. The company works closely with these partners to achieve synergies and translate research findings into marketable products and therapies faster. In conclusion, BELLUS Health Inc is a company with a diverse product portfolio in the field of medicine and biosciences. The company prioritizes collaboration with partners and research institutions to develop innovative treatment methods and therapies. Cooperation with pharmacies and hospitals allows the company to facilitate patient access to the latest medical developments.

Liikevaihtoa ei voida laskea BELLUS Health:lle tällä hetkellä.

Voittoa ei voida laskea BELLUS Health:lle tällä hetkellä.

P/E-suhdetta ei voida laskea BELLUS Health:lle tällä hetkellä.

P/S-suhdetta ei voida laskea BELLUS Health:lle tällä hetkellä.

BELLUS Health:n Eulpool-laatuscore on 2/10.

BELLUS Health:n ISIN on CA07987C2040. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

BELLUS Health:n WKN on A2PQKK. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

BELLUS Health:n ticker on BLU.TO. Tämä pörssinoteeraus käytetään BELLUS Health-osakkeiden kauppaan pörssissä.

BELLUS Health maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

BELLUS Health kuuluu sektoriin 'Terveydenhuolto'.

BELLUS Health:n osingot jaetaan valuutassa USD.